FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New ...

The FDA rejected Applied Therapeutics’ experimental treatment, govorestat, for a rare disease called classic galactosemia, ...

Advanz Pharma's liver treatment Ocaliva lost EU marketing authorization following a court decision. The drug, used for ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...

Idor­sia is mak­ing moves to stretch its cash re­serves fur­ther. The Swiss drug­mak­er said it is nar­row­ing its ...

Novartis is laying off 139 employees in East Hanover, NJ, primarily affecting commercial field sales teams working on Xolair (allergy/asthma) and Tafinlar-Mekinist (cancer) treatments. The cuts, ...

Recursion Pharmaceuticals laid off under 20% of staff following merger with Exscientia. Oxford Nanopore partners with UK Biobank for epigenetic dataset project. Portage Biotech continues strategic ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...